Trial reportAmerican journal of respiratory and critical care medicine2014
Noninvasive saliva-based EGFR gene mutation detection in patients with lung cancer.
Trial report in American journal of respiratory and critical care medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Salivary biomarkers for diagnosis of systemic diseases and malignant tumors. A systematic review.Medicina oral, patologia oral y cirugia bucal · 2020Pooled it
- Salivary biomarkers for cancer diagnosis: a meta-analysis.Annals of medicinePooled it
- Electric Field-Induced Release and Measurement Liquid Biopsy for Noninvasive Early Lung Cancer Assessment.The Journal of molecular diagnostics : JMD · 2018Trial
- Study of the Spectral-Luminescent Properties of Saliva in Patients With Lung Cancer.Journal of biophotonics · 2026Article
- Electric Field-Induced Release and Measurement Liquid Biopsy of Urinary Transcriptomics and Key Proteins from Normal and High-risk Pregnant Women.Reproductive sciences (Thousand Oaks, Calif.) · 2026Article
- Electrochemical liquid biopsy across cancer care pathway.The journal of liquid biopsy · 2026Review
- Biosensors for Cancer and Inflammation: Whole-Cell Biosensors for Soluble Molecules.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Functional regulatory roles of HNF1B in promoting cell proliferation, migration, invasion and fate decision of hepatocellular carcinoma.BMC cancer · 2025Article
- Liquid biopsy - a narrative review with an update on current US governmental clinical trials targeting immunotherapy.Future science OA · 2025Review
- Review
- Salivary biomarkers: a promising approach for predicting immunotherapy response in head and neck cancers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- RNA transcripts in salivary extracellular vesicle cargo isolated from aged populations.Frontiers in aging · 2025Article
- Direct detection of 4-dimensions of SARS-CoV-2: infection (vRNA), infectivity (antigen), binding antibody, and functional neutralizing antibody in saliva.Scientific reports · 2024Article
- Review
- Computational and experimental microfluidics: Total analysis system for mixing, sorting, and concentrating particles and cells.APL bioengineering · 2024Article
- Rapid Nucleic Acid Diagnostic Technology for Pandemic Diseases.Molecules (Basel, Switzerland) · 2024Review
- Enhancing saliva diagnostics: The impact of amylase depletion on MALDI-ToF MS profiles as applied to COVID-19.Journal of mass spectrometry and advances in the clinical lab · 2024Article
- Microbes for lung cancer detection: feasibility and limitations.Frontiers in oncology · 2024Review
- Direct Detection of 4-Dimensions of SARS-CoV-2: Infection (vRNA), Infectivity (Antigen), Binding Antibody, and Functional Neutralizing Antibody in Saliva.Research square · 2023Article
- Multi-faceted attributes of salivary cell-free DNA as liquid biopsy biomarkers for gastric cancer detection.Biomarker research · 2023Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
rationaleConstitutive activation of the epidermal growth factor receptor (EGFR) is prevalent in epithelial cancers, particularly in non-small cell lung carcinoma (NSCLC). Mutations identified in EGFR predict the sensitivity to EGFR-targeted therapy. Detection of these mutations is mainly based on tissue biopsy, which is invasive, expensive, and time consuming.
objectivesNoninvasive, real-time, inexpensive detection and monitoring of EGFR mutations in patients with NSCLC is highly desirable.
methodsWe developed a novel core technology, electric field-induced release and measurement (EFIRM), which relies on a multiplexible electrochemical sensor that can detect EGFR mutations directly in bodily fluids. MEASUREMENTS AND MAIN
resultsWe established EFIRM for the detection of the EGFR mutations in vitro and correlated the results with tumor size from xenografted mice. In clinical application, we demonstrated that EFIRM could detect EGFR mutations in the saliva and plasma of 22 patients with NSCLC. Finally, a blinded test was performed on saliva samples from 40 patients with NSCLC. The receiver operating characteristic analysis indicated that EFIRM detected the exon 19 deletion with an area under the curve of 0.94 and the L858R mutation with an area under the curve of 0.96.
conclusionsOur data indicate that EFIRM is effective, accurate, rapid, user-friendly, and cost effective for the detection of EGFR mutations in the saliva of patients with NSCLC. We termed this saliva-based EGFR mutation detection (SABER).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.